Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits

Journal Paper/Review - Feb 5, 2019


Xin B, Groll M, van der Marel G, Driessen C, Florea B, Kisselev A, Weyburne E, Janssens M, Du Y, Espinal C, Maurits E, Heinemeyer W, de Bruin G, Huber E, Overkleeft H. Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits. J Med Chem 2019; 62:1626-1642.
Journal Paper/Review (English)
J Med Chem 2019; 62
Publication Date
Feb 5, 2019
Issn Electronic
Brief description/objective

Subunit-selective proteasome inhibitors are valuable tools to assess the biological and medicinal relevance of individual proteasome active sites. Whereas the inhibitors for the β1c, β1i, β5c, and β5i subunits exploit the differences in the substrate-binding channels identified by X-ray crystallography, compounds selectively targeting β2c or β2i could not yet be rationally designed because of the high structural similarity of these two subunits. Here, we report the development, chemical synthesis, and biological screening of a compound library that led to the identification of the β2c- and β2i-selective compounds LU-002c (4; IC β2c: 8 nM, IC β2i/β2c: 40-fold) and LU-002i (5; IC β2i: 220 nM, IC β2c/β2i: 45-fold), respectively. Co-crystal structures with β2 humanized yeast proteasomes visualize protein-ligand interactions crucial for subunit specificity. Altogether, organic syntheses, activity-based protein profiling, yeast mutagenesis, and structural biology allowed us to decipher significant differences of β2 substrate-binding channels and to complete the set of subunit-selective proteasome inhibitors.